Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Management of patients with advanced-stage HER2-positive breast cancer: current evidence and future perspectives
Antonio Marra, Sarat Chandarlapaty, Shanu Modi
Nature Reviews Clinical Oncology (2024) Vol. 21, Iss. 3, pp. 185-202
Closed Access | Times Cited: 43

Showing 1-25 of 43 citing articles:

Development and evaluation of a human CD47/HER2 bispecific antibody for Trastuzumab-resistant breast cancer immunotherapy
Binglei Zhang, Jianxiang Shi, Xiaojing Shi, et al.
Drug Resistance Updates (2024) Vol. 74, pp. 101068-101068
Closed Access | Times Cited: 14
The efficacy of sacituzumab govitecan and trastuzumab deruxtecan on stable and active brain metastases in metastatic breast cancer patients—a multicenter real-world analysis
Dominik Dannehl, Dominik A. Jakob, Franziska Mergel, et al.
ESMO Open (2024) Vol. 9, Iss. 5, pp. 102995-102995
Open Access | Times Cited: 11
Unlocking the Potential: Biomarkers of Response to Antibody-Drug Conjugates
Liliana Ascione, Lorenzo Guidi, Ajay Prakash, et al.
American Society of Clinical Oncology Educational Book (2024) Vol. 44, Iss. 3
Closed Access | Times Cited: 11
STING in Cancer Immunoediting: Modeling Tumor-Immune Dynamics Throughout Cancer Development
Xiao Zhang, Yan Chen, Xi Liu, et al.
Cancer Letters (2025) Vol. 612, pp. 217410-217410
Open Access | Times Cited: 1
Endogenous Protein‐Modified Gold Nanorods as Immune‐Inert Biomodulators for Tumor‐Specific Imaging and Therapy
Chunyan Fang, Yueming Cai, He Cui, et al.
Advanced Healthcare Materials (2025)
Open Access | Times Cited: 1
Open questions, current challenges, and future perspectives in targeting human epidermal growth factor receptor 2-low breast cancer
Giuseppe Curigliano, Rebecca Dent, H. Earle, et al.
ESMO Open (2024) Vol. 9, Iss. 4, pp. 102989-102989
Open Access | Times Cited: 6
Antibody–drug conjugates in cancer therapy: mechanisms and clinical studies
Jun He, Xianghua Zeng, Chunmei Wang, et al.
MedComm (2024) Vol. 5, Iss. 8
Open Access | Times Cited: 5
Preclinical Evaluation of HER2-Targeting DARPin G3: Impact of Albumin-Binding Domain (ABD) Fusion
Sergey M. Deyev, Maryam Oroujeni, Javad Garousi, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 8, pp. 4246-4246
Open Access | Times Cited: 4
Impact of HER2-targeting antibody drug conjugates in treatment strategies for patients with breast cancer
H Ma, Jianbin Li
Heliyon (2025) Vol. 11, Iss. 3, pp. e41590-e41590
Open Access
Targeting SLC7A11-mediated cysteine metabolism for the treatment of trastuzumab resistant HER2 positive breast cancer
Yijia Hua, Ningjun Duan, Chunxiao Sun, et al.
(2025)
Open Access
Targeting SLC7A11-mediated cysteine metabolism for the treatment of trastuzumab resistant HER2 positive breast cancer
Yijia Hua, Ningjun Duan, Chunxiao Sun, et al.
(2025)
Open Access
CD36 inhibition enhances the anti-proliferative effects of PI3K inhibitors in PTEN-loss anti-HER2 resistant breast cancer cells
You‐Yu Liu, Wei-Lun Huang, Sin-Tian Wang, et al.
Cancer & Metabolism (2025) Vol. 13, Iss. 1
Open Access
A new strategy to HER2-specific antibody discovery through artificial intelligence-powered phage display screening based on the Trastuzumab framework
Mancang Zhang, Qiangzhen Yang, Jiangrong Lou, et al.
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease (2025) Vol. 1871, Iss. 5, pp. 167772-167772
Closed Access
Multi-omics and drug development
Saira Hamid, Ajaz A. Bhat, Muzafar Rasool Bhat, et al.
Elsevier eBooks (2025), pp. 147-171
Closed Access
Antibody-drug conjugates in breast cancer: current evidence and future directions
Ning Li, Lu Yang, Zixuan Zhao, et al.
Experimental Hematology and Oncology (2025) Vol. 14, Iss. 1
Open Access
Monoclonal Antibodies in Clinical Trials for Breast Cancer Treatment
Rahaman Shaik, V. Pavani Sai Mounika, S. Begum, et al.
Monoclonal Antibodies in Immunodiagnosis and Immunotherapy (2025)
Closed Access
Alkaline phosphatase-responsive peptide amphiphiles promote the apoptosis of HER2-positive breast cancer cells via increased drug accumulation
Aimei Li, Tian Xue, Feihu Hu, et al.
Colloids and Surfaces A Physicochemical and Engineering Aspects (2025), pp. 136848-136848
Closed Access
Predictive significance of 18F-FDG PET/CT metabolic parameters for the expression level of HER2 in gastric cancer
Shilai Zhang, Mo Shaozhou, W. Linlin, et al.
Frontiers in Oncology (2025) Vol. 15
Open Access
HER2 and Epigenetic Modifications in Tumorigenesis: Mechanisms and Therapeutic Implications
Zhoujie Ye, Hyeong Gon Yu, Liping Zhu, et al.
IntechOpen eBooks (2025)
Closed Access
PAK5 promotes the trastuzumab resistance by increasing HER2 nuclear accumulation in HER2-positive breast cancer
Xin Zhao, Yang Li, Hongyan Zhang, et al.
Cell Death and Disease (2025) Vol. 16, Iss. 1
Open Access
Targeting SLC7A11-mediated cysteine metabolism for the treatment of trastuzumab resistant HER2 positive breast cancer
Yijia Hua, Ningjun Duan, Chunxiao Sun, et al.
(2025)
Open Access
Excellent efficacy of trastuzumab deruxtecan in a patient with HER2-positive advanced breast cancer complicated by pulmonary lymphangitic carcinomatosis: a case report and literature review
Simin Luo, Jie Chai, Linxiaoxiao Ding, et al.
Frontiers in Pharmacology (2025) Vol. 16
Open Access
Depicting Biomarkers for HER2-Inhibitor Resistance: Implication for Therapy in HER2-Positive Breast Cancer
Alvan Cai, Yuan Chen, Lily S. Wang, et al.
Cancers (2024) Vol. 16, Iss. 15, pp. 2635-2635
Open Access | Times Cited: 2
De-escalation of neoadjuvant taxane and carboplatin therapy in HER2-positive breast cancer with dual HER2 blockade: a multicenter real-world experience in China
Song Wu, Li Bian, Haibo Wang, et al.
World Journal of Surgical Oncology (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 2
YTHDF1 boosts the lactate accumulation to potentiate cervical cancer cells immune escape
Jing Xiong, Ling He, Xiaoshan Chai, et al.
Cell Death and Disease (2024) Vol. 15, Iss. 11
Open Access | Times Cited: 2
Page 1 - Next Page

Scroll to top